伊索林德拉克通过抑制巨细胞中NF-κB介导的炎症来减轻动脉样硬化
Yudie Yang1, Sirui Shen1, Yue Guan1
1Department of Cardiology and Medical Research Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
International immunopharmacology
|November 18, 2025
概括
来自Lindera聚合物的伊索林德拉克 (ILL) 有效地减少小鼠的动脉样硬化病变和炎症. 这种天然化合物抑制了巨细胞对氧化LDL的吸收,为治疗动脉样硬化提供了潜在的新策略.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 动脉样硬化是一种由脂质沉积和炎症驱动的慢性炎症性动脉疾病.
- 来自林德拉聚合物的异双乳 (ILL) 具有抗炎和抗增殖的特性.
- 在动脉样硬化中ILL的治疗潜力需要进一步研究.
研究的目的:
- 在动脉样硬化小鼠模型中评估伊索林德拉克 (ILL) 的治疗疗效.
- 阐明ILL在动脉样硬化中的作用的潜在分子机制.
- 探索ILL作为动脉样硬化的潜在治疗方法.
主要方法:
- 在使用高脂肪/高胆固醇饮食的ApoE-/-小鼠中诱导了动脉样硬化.
- 通过腹腔内注射,小鼠接受了不同剂量的ILL治疗.
- 在体外研究中评估了巨细胞的oxLDL吸收,RNA-seq分析了NF-κB通路调节.
主要成果:
- 在小鼠中,ILL显著降低了动脉样硬化病变的大小和泡细胞含量.
- 治疗ILL抑制了大动脉组织中炎症细胞的透.
- 在体外,ILL抑制了巨细胞的氧化低密度脂蛋白 (oxLDL) 摄取,并调节了NF-κB信号通路.
结论:
- 伊索林德拉克 (ILL) 在延缓动脉样硬化进展方面显示出显著的治疗潜力.
- 通过调节NF-κB通路,ILL可以减少促炎因素和食尸体受体表达.
- ILL代表了新型动脉样硬化治疗策略的有希望的候选人.
相关概念视频
01:38Inflammation
61.5K
Overview
61.5K
01:26Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
01:30Atherosclerosis I: Introduction
835
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
835
02:26NF-κB-dependent Signaling Pathway
9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
465
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
465